Eva Wagner-Drouet

1.3k total citations
28 papers, 175 citations indexed

About

Eva Wagner-Drouet is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Eva Wagner-Drouet has authored 28 papers receiving a total of 175 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 14 papers in Oncology and 8 papers in Immunology. Recurrent topics in Eva Wagner-Drouet's work include Hematopoietic Stem Cell Transplantation (13 papers), CAR-T cell therapy research (10 papers) and Acute Myeloid Leukemia Research (9 papers). Eva Wagner-Drouet is often cited by papers focused on Hematopoietic Stem Cell Transplantation (13 papers), CAR-T cell therapy research (10 papers) and Acute Myeloid Leukemia Research (9 papers). Eva Wagner-Drouet collaborates with scholars based in Germany, Netherlands and France. Eva Wagner-Drouet's co-authors include Daniel Heudobler, Peter Borchmann, Irene Schmidtmann, Andréas Mackensen, Liane Preußner, Andreas Kreft, Helmut Neumann, Erol Wiegert, Benjamin Rengstl and Markus P. Radsak and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Eva Wagner-Drouet

23 papers receiving 173 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva Wagner-Drouet Germany	8	92	81	55	47	20	28	175
Xiebing Bao China	10	119 1.3×	89 1.1×	53 1.0×	42 0.9×	29 1.4×	35	219
Patric Teodorescu Romania	10	90 1.0×	44 0.5×	64 1.2×	33 0.7×	23 1.1×	30	186
Irene García‐Cadenas Spain	7	103 1.1×	133 1.6×	64 1.2×	52 1.1×	23 1.1×	11	217
Sameer Melinkeri India	9	62 0.7×	58 0.7×	66 1.2×	81 1.7×	9 0.5×	24	221
Jian‐Hui Qiao China	7	137 1.5×	67 0.8×	22 0.4×	55 1.2×	31 1.6×	26	185
Friso Calkoen Netherlands	8	49 0.5×	73 0.9×	28 0.5×	31 0.7×	13 0.7×	28	148
Uri Greenbaum Israel	9	37 0.4×	117 1.4×	37 0.7×	55 1.2×	11 0.6×	26	232
Hamed Soleimani Samarkhazan Iran	9	59 0.6×	90 1.1×	131 2.4×	57 1.2×	11 0.6×	36	259
David M. Cordas dos Santos Germany	8	49 0.5×	251 3.1×	82 1.5×	45 1.0×	12 0.6×	16	304
Kirsty Cuthill United Kingdom	8	87 0.9×	70 0.9×	59 1.1×	45 1.0×	11 0.6×	18	189

Countries citing papers authored by Eva Wagner-Drouet

Since Specialization

Citations

This map shows the geographic impact of Eva Wagner-Drouet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Wagner-Drouet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Wagner-Drouet more than expected).

Fields of papers citing papers by Eva Wagner-Drouet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Wagner-Drouet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Wagner-Drouet. The network helps show where Eva Wagner-Drouet may publish in the future.

Co-authorship network of co-authors of Eva Wagner-Drouet

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Wagner-Drouet. A scholar is included among the top collaborators of Eva Wagner-Drouet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Wagner-Drouet. Eva Wagner-Drouet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomas, Simone, Martin Wermke, Vladan Vučinić, et al.. (2025). First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms. Cancers. 17(18). 2968–2968.

Zeiser, Robert, James L.M. Ferrara, Udo Holtick, et al.. (2025). The Phase 2 Stargaze Trial of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Combination with Ruxolitinib for Steroid-Refractory Gastrointestinal (GI) Acute Graft-Versus-Host Disease (aGvHD): Comparisons with a MAGIC Control Cohort. Transplantation and Cellular Therapy. 31(2). S278–S279.

Esteve, Jordi, Arnon Nagler, Myriam Labopin, et al.. (2025). Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. American Journal of Hematology. 100(6). 954–962. 2 indexed citations

Beelen, Dietrich W., Simona Iacobelli, Linda Köster, et al.. (2024). Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison. Bone Marrow Transplantation. 59(5). 670–679. 3 indexed citations

Gagelmann, Nico, Robert Zeiser, Matthias Stelljes, et al.. (2024). Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation. Transplantation and Cellular Therapy. 30(10). 1011.e1–1011.e13. 2 indexed citations

Ayuk, Francis, Eva Wagner-Drouet, Daniel Wolff, et al.. (2024). Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study. Bone Marrow Transplantation. 59(8). 1092–1096. 2 indexed citations

Barba, Pere, Mi Kwon, Julia Weinmann‐Menke, et al.. (2024). POS0046 PRELIMINARY RESULTS OF AN OPEN-LABEL, MULTICENTRE, PHASE 1/2 STUDY TO ASSESS SAFETY, EFFICACY AND CELLULAR KINETICS OF YTB323 (RAPCABTAGENE AUTOLEUCEL), A RAPIDLY MANUFACTURED CAR T-CELL THERAPY TARGETING CD19 ON B CELLS, FOR SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 83. 327–328. 5 indexed citations

Canales, Miguel, Pier Luigi Canonico, Guillaume Cartron, et al.. (2023). Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Frontiers in Medicine. 10. 1128295–1128295. 12 indexed citations

Schubert, Maria‐Luisa, Wolfgang Bethge, Francis Ayuk, et al.. (2023). Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study. Blood Advances. 7(20). 6191–6195. 9 indexed citations

10.

Singh, Satwinder, Eva Wagner-Drouet, Uwe Platzbecker, et al.. (2023). P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE. HemaSphere. 7(S3). e95344a6–e95344a6. 1 indexed citations

11.

Loke, Justin, Myriam Labopin, Charles Craddock, et al.. (2022). Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer. 128(15). 2922–2931. 31 indexed citations

12.

Wagner-Drouet, Eva, Daniel Teschner, Christine Wolschke, et al.. (2021). Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics. 11(2). 312–312. 1 indexed citations

13.

Hauptrock, Beate, Oliver Kriege, Wilfried Wagner, et al.. (2021). Alloimmune Myositis as Paraneoplastic Complication of an Oral Squamous Cell Carcinoma After Severe Chronic Graft vs Host Disease or a Manifestation of Chronic Graft vs Host Disease? A Case Report and Literature Discussion. Transplantation Proceedings. 53(4). 1365–1368. 1 indexed citations

14.

Haanen, J.B.A.G., Andréas Mackensen, Christian Koenecke, et al.. (2021). LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors. Annals of Oncology. 32. S1392–S1392. 7 indexed citations

15.

Bazarbachi, Abdul Hamid, Myriam Labopin, Nicolaus Kröger, et al.. (2021). Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 21(12). 831–840. 2 indexed citations

16.

Kreft, Andreas, Eva Wagner-Drouet, Arne Kandulski, et al.. (2021). An investigation of the diagnostic, predictive, and prognostic impacts of three colonic biopsy grading systems for acute graft versus host disease. PLoS ONE. 16(8). e0256543–e0256543. 5 indexed citations

17.

Giebel, Sebastian, Myriam Labopin, Gèrard Socié, et al.. (2020). Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation. 56(5). 1047–1055. 1 indexed citations

18.

Hölig, Kristina, Helmuth Schmidt, Gero Hütter, et al.. (2020). Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial. Bone Marrow Transplantation. 56(3). 635–645. 11 indexed citations

19.

Michel, Christian, Daniel Teschner, Irene Schmidtmann, et al.. (2019). Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. Scientific Reports. 9(1). 19911–19911. 19 indexed citations

20.

Kreft, Andreas, et al.. (2019). Histologic diagnosis and grading of esophageal acute graft-versus-host disease. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 474(3). 325–332. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact